Methods and compositions for the treatment of CNS-related conditions
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A01N-047/28
A01N-031/15
A61K-031/17
A61K-027/00
A61K-009/00
출원번호
US-0753769
(2010-04-02)
등록번호
US-8293794
(2012-10-23)
발명자
/ 주소
Went, Gregory T.
Fultz, Timothy J.
Meyerson, Laurence R.
출원인 / 주소
Adamas Pharmaceuticals, Inc.
대리인 / 주소
Wilson Sonsini Goodrich & Rosati
인용정보
피인용 횟수 :
18인용 특허 :
80
초록
The present invention provides novel methods and compositions for the treatment and prevention of CNS-related conditions. One of the CNS-related conditions treated by the methods and compositions of the invention is Alzheimer's disease.
대표청구항▼
1. A pharmaceutical composition comprising: (a) 5 to 40 mg memantine or a pharmaceutically acceptable salt thereof provided in an extended release dosage form, wherein said extended release memantine or pharmaceutically acceptable salt thereof provides a change in plasma concentration as a function
1. A pharmaceutical composition comprising: (a) 5 to 40 mg memantine or a pharmaceutically acceptable salt thereof provided in an extended release dosage form, wherein said extended release memantine or pharmaceutically acceptable salt thereof provides a change in plasma concentration as a function of time (dC/dT) in a defined time period of 0 to 6 hours after administration, as measured in a single-dose human PK study, that is less than about 50% of the dC/dT provided by the same quantity of an immediate release form of memantine during said defined time period; and(b) a therapeutically effective amount of an ACheI or a pharmaceutically acceptable salt thereof selected from the group consisting of donepezil, rivastigmine and galantamine. 2. A pharmaceutical composition of claim 1, wherein the ACheI is donepezil. 3. The composition of claim 1 wherein the concentration profile is further characterized by a maximum memantine plasma concentration to mean memantine plasma concentration ratio (Cmax/Cmean) of about 2.5 to 2 at 1 hour to at least 6 hours after administration. 4. The composition of claim 1, wherein at least 98% of the memantine is in an extended release form. 5. The composition of claim 1, wherein the composition is a capsule and wherein the memantine, or pharmaceutically acceptable salt thereof, is formulated as pellets. 6. The composition of claim 5, wherein the pellets comprise an extended release coating. 7. The composition of claim 6, wherein the extended release coating comprises an insoluble matrix polymer and a water soluble material. 8. The composition of claim 7, wherein the insoluble matrix polymer comprises ethyl cellulose and the water soluble material comprises polyvinylpyrrolidone. 9. The composition of claim 1 comprising 12.5-40 mg memantine or a pharmaceutically acceptable salt thereof. 10. The composition of claim 1 comprising 25-40 mg memantine or a pharmaceutically acceptable salt thereof. 11. The composition of claim 1, wherein the extended release memantine dosage form further comprises, ethyl cellulose, polyethylene glycol, hydroxypropylmethyl cellulose and polyvinylpyrrolidone. 12. The composition of claim 1, wherein the ACheI is donepezil or a pharmaceutically acceptable salt thereof. 13. The composition of claim 12 wherein the donepezil or pharmaceutically acceptable salt thereof is in an immediate release form. 14. The composition of claim 1, wherein said extended release memantine or pharmaceutically acceptable salt thereof has an in vitro dissolution of less than 30% in one hour, less than 40% in two hours and greater than 40% in six hours as measured using a USP type 2 (paddle) dissolution system at 50 rpm, at a temperature of 37±0.5° C. with water as a dissolution medium. 15. A pharmaceutical composition comprising: (a) 5 to 40 mg memantine or a pharmaceutically acceptable salt thereof provided in an extended release dosage form, wherein said extended release memantine or pharmaceutically acceptable salt thereof provides a change in plasma concentration as a function of time (dC/dT) that is less than about 50% of the dC/dT provided by the same quantity of an immediate release form of memantine during said defined time period, wherein the dC/dT is measured in a single dose human PK study between the time period of 0 to Tmax of the immediate release form of memantine; and(b) a therapeutically effective amount of an ACheI or a pharmaceutically acceptable salt thereof selected from the group consisting of donepezil, rivastigrnine and galantamine. 16. A pharmaceutical composition of claim 15, wherein the ACheI is donepezil. 17. The composition of claim 15, wherein the concentration profile is further characterized by a maximum memantine plasma concentration to mean memantine plasma concentration ratio (Cmax/Cmean) of about 2.5 to 2 at 1 hour to at least 6 hours after administration. 18. The composition of claim 15, wherein at least 98% of the memantine is in an extended release form. 19. The composition of claim 15, wherein the composition is a capsule and wherein the memantine, or pharmaceutically acceptable salt thereof, is formulated as pellets. 20. The composition of claim 19, wherein the pellets comprise an extended release coating. 21. The composition of claim 20, wherein the extended release coating comprises an insoluble matrix polymer and a water soluble material. 22. The composition of claim 21, wherein the insoluble matrix polymer comprises ethyl cellulose and the water soluble material comprises polyvinylpyrrolidone. 23. The composition of claim 15, comprising 12.5-40 mg memantine or a pharmaceutically acceptable salt thereof. 24. The composition of claim 15, comprising 25-40 mg memantine or a pharmaceutically acceptable salt thereof. 25. The composition of claim 15, wherein the extended release memantine dosage form further comprises, ethyl cellulose, polyethylene glycol, hydroxypropylmethyl cellulose and polyvinylpyrrolidone. 26. The composition of claim 15, wherein the ACheI is donepezil or a pharmaceutically acceptable salt thereof. 27. The composition of claim 26, wherein the donepezil or pharmaceutically acceptable salt thereof is in an immediate release form. 28. The composition of claim 15, wherein said extended release memantine or pharmaceutically acceptable salt thereof has an in vitro dissolution of less than 30% in one hour, less than 40% in two hours and greater than 40% in six hours as measured using a USP type 2 (paddle) dissolution system at 50 rpm, at a temperature of 37±0.5° C. with water as a dissolution medium.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (80)
Kelleher Judith A. ; Maples Kirk R. ; Dykman Alina ; Zhang Yong-Kang ; Wilcox Allan L. ; Levell Julian, .alpha.-aryl-N-alkylnitrones and pharmaceutical compositions containing the same.
Bormann Joachim (Frankfurt DEX) Gold Markus R. (Nauheim DEX) Schatton Wolfgang (Eschborn DEX), Adamantane derivatives in the prevention and treatment of cerebral ischemia.
Rudnic Edward M. ; Belendiuk George W. ; McCarty John ; Wassink Sandra ; Couch Richard A., Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine.
Guittard George V. (Cupertino CA) Wong Patrick S. L. (Palo Alto CA) Kuczynski Anthony L. (Mountain View CA) Kidney David J. (Palo Alto CA), Antiviral therapy.
Nickel Bernd (Mhltal DEX) Lobisch Michael (Ober-Ramstadt DEX) Szelenyi Istvan (Schwaig DEX) Engel Jrgen (Alzenau DEX) Emig Peter (Niederdorfelden DEX) Pergande Gabriela (Offenbach DEX), Combination medication containing flupirtin and morphine for the treatment of pain and the prevention of morphine depend.
Cordi Alex A. (St. Louis MO) Jans Michel R. (Brussels BEX), Composition containing D-cycloserine and D-alanine for memory and learning enhancement or treatment of a cognitive or ps.
Wong, Patrick S. L.; Dong, Liang C.; Wan, Jiansheng, Conversion of liquid filled gelatin capsules into controlled release systems by multiple coatings.
Cordi Alex A. (St. Louis MO) Handelmann Gail E. (Chesterfield MO) Monahan Joseph B. (Black Jack MO), D-cycloserine and its prodrugs as cognitive enhancers.
Prausnitz, Mark R.; Allen, Mark G.; Henry, Sebastien; McAllister, Devin V.; Ackley, Donald E.; Jackson, Thomas, Devices and methods for enhanced microneedle penetration of biological barriers.
Edgren David E. (El Granada) Carpenter Howard A. (Palo Alto) Bhatti Gurdish K. (Fremont) Ayer Atul D. (Palo Alto CA), Dosage form for treating central nervous system disorders.
Edgren David E. (El Granada CA) Carpenter Howard A. (Palo Alto CA) Bhatti Gurdish K. (Fremont CA) Ayer Atul D. (Palo Alto CA), Dosage form indicated for the management of abnormal posture, tremor and involuntary movement.
Edgren David E. (El Granada) Carpenter Howard A. (Palo Alto) Bhatti Gurdish K. (Fremont) Ayer Atul D. (Palo Alto CA), Dosage form indicated for the management of abnormal posture, tremor and involuntary movement.
Nrnberg Eberhard (Uttenreuth/Welher DEX) Seiller Erhard (Nidderau DEX) Ritsert Stefan (Eberbach DEX), Memantine-containing solid pharmaceutical dosage forms having an extended two-stage release profile and production there.
Lam, Andrew C.; Shivanand, Padmaja; Ayer, Atul D.; Weyers, Richard G.; Gupta, Suneel K.; Guinta, Diane R.; Christopher, Carol A.; Saks, Samuel R.; Hamel, Lawrence G.; Wright, Jeri D.; Hatamkhany, Zah, Methods and devices for providing prolonged drug therapy.
Chen, Guohua; Lautenbach, Scott D.; Dionne, Keith E.; Jordan, Scott D.; Berry, Steve A.; Rodenberger, Craig I.; Ayer, Rupal, Osmotic delivery system, osmotic delivery system semipermeable body assembly, and method for controlling delivery rate of beneficial agents from osmotic delivery systems.
Lobisch Michael (Ober-Ramstadt DEX) Venhaus Ralph (Heppenheim DEX) Nickel Bernd (Mhltal DEX) Szelenyi Istvan (Schwaig DEX) Engel Jrgen (Alzenau DEX) Emig Peter (Niederdorfelden DEX), Pharmaceutical composition comprising flupirtine and its use to combat muscular tension.
Buxton Ian R. (Cambridge GBX) Critchley Helen (Cambridge GBX) Leslie Stewart T. (Cambridge GBX) Prater Derek A. (Cambridge GBX) Miller Ronald B. (Basle CHX) Malkowska Sandra T. A. (Cambridge GBX), Pharmaceutical spheroid formulation.
Rudnic Edward M. ; Burnside Beth A. ; Flanner Henry H. ; Wassink Sandra E. ; Couch Richard A. ; Pinkett Jill E., Soluble form osmotic dose delivery system.
Peery, John R.; Dionne, Keith E.; Eckenhoff, James B.; Landrau, Felix A.; Lautenbach, Scott D.; Magruder, Judy A.; Wright, Jeremy C., Sustained delivery of an active agent using an implantable system.
Hanns Ludwig DE; Detlef Dietrich DE; Hinderk M. Emrich DE; Liv Bode DE, USE OF ADAMANTANE AMINES OR STRUCTURALLY SIMILAR COMPOUNDS FOR COMBATING BORNA DISEASE VIRUS AND FOR THE PREVENTION AND TREATMENT OF AFFECTIVE DISEASES AND OTHER DISORDERS ASSOCIATED WITH BDV INFECTI.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.